Back

Shire

01/02/2014

Shire – Introduction

In Q1/2014 Shire is expected to report its Phase III data for Vyvanse (for binge eating disorders) and Lifitegrast (for dry eye disease). Shire has a strong R&D pipeline for orphan drugs which further enhances its attractiveness as a potential investment.

Link to the comapny profile SHP
Link to the biotechnlogy report

Back

Related articles

Berkshire Hathaway Inc.

07/07/2025

Berkshire Hathaway Inc. is a multinational conglomerate holding company based in Omaha, Nebraska, best known for its legendary chairman and CEO, Warren Buffett. Originally a textile company, it was transformed...

Read More >>>

US regional bank

09/05/2023

Over the last few months, regional US banks balance sheets remained under severe pressure as clients were searching for security and higher yields. Some institutions, such as Charles Schwab, which...

Read More >>>

Berkshire Hathaway Inc. – nothing new but still performing

03/04/2022

Berkshire Hathaway is the relatively boring value pick. The company owns a collection of about 60 subsidiary businesses, including household names such as GEICO, Duracell, and Dairy Queen, just to...

Read More >>>

Shire plc – Part 1

04/09/2013

Description: Shire is a small Irish based specialty bio-pharmaceutical company with a focus on developing therapeutic treatments for central nervous system, metabolic and gastro-intestinal conditions. The company is organized into...

Read More >>>

Shire plc – Part 2

04/09/2013

Company profile, investment opportunity and asset management integration: Metric Rating Operational risks: Average Expected growth: Average Long term value creation: Excellent Positive competitive advantage: Outstanding Management excellence: Average Financial strength:...

Read More >>>